BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 16952649)

  • 1. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified?
    Divrik RT; Akdoğan B; Ozen H; Zorlu F
    J Urol; 2006 Oct; 176(4 Pt 1):1424-29; discussion 1429-30. PubMed ID: 16952649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.
    Ondrus D; Ondrusova M; Hornak M; Matoska J
    Neoplasma; 2007; 54(5):437-42. PubMed ID: 17688374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
    Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
    J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres.
    Ernst DS; Brasher P; Venner PM; Czaykowski P; Moore MJ; Reyno L; Winquist E; Segal R; Hao D
    Can J Urol; 2005 Apr; 12(2):2575-80. PubMed ID: 15877938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance.
    Warde P; Gospodarowicz MK; Banerjee D; Panzarella T; Sugar L; Catton CN; Sturgeon JF; Moore M; Jewett MA
    J Urol; 1997 May; 157(5):1705-9; discussion 1709-10. PubMed ID: 9112510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
    Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
    J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup.
    Nicolai N; Pizzocaro G
    J Urol; 1995 Sep; 154(3):1045-9. PubMed ID: 7637051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumors (NSGCTT).
    Ondrus D; Goncalves F; Kausitz J; Mat'oska J; Belan V
    Neoplasma; 1996; 43(3):195-7. PubMed ID: 8841507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection.
    Hermans BP; Sweeney CJ; Foster RS; Einhorn LE; Donohue JP
    J Urol; 2000 Jun; 163(6):1721-4. PubMed ID: 10799168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
    Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
    Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort.
    Daugaard G; Gundgaard MG; Mortensen MS; Agerbæk M; Holm NV; Rørth M; von der Maase H; Christensen IJ; Lauritsen J
    J Clin Oncol; 2014 Dec; 32(34):3817-23. PubMed ID: 25267754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
    Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
    J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study.
    Aparicio J; Germà JR; García del Muro X; Maroto P; Arranz JA; Sáenz A; Barnadas A; Dorca J; Gumà J; Olmos D; Bastús R; Carles J; Almenar D; Sánchez M; Paz-Ares L; Satrústegui JJ; Mellado B; Balil A; López-Brea M; Sánchez A;
    J Clin Oncol; 2005 Dec; 23(34):8717-23. PubMed ID: 16260698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the presence of extranodal extension in pathological stage B1 nonseminomatous germ cell tumor necessitate adjuvant chemotherapy?
    Beck SD; Cheng L; Bihrle R; Donohue JP; Foster RS
    J Urol; 2007 Mar; 177(3):944-6. PubMed ID: 17296383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection.
    Spiess PE; Brown GA; Liu P; Tu SM; Tannir NM; Evans JG; Kamat AM; Kassouf W; Pisters LL
    J Urol; 2007 Jan; 177(1):131-8. PubMed ID: 17162023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of patients after retroperitoneal lymphadenectomy for clinical stage I nonseminomatous germ cell tumour of the testis.
    Hornák M; Zvara V; Ondrus D; Bárdos A
    Czech Med; 1987; 10(2):109-16. PubMed ID: 2820669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of stage I testicular nonseminomatous germ cell tumors with an embryonic carcinomatous component. 18 cases].
    Drianno N; Robert M; Legouffe E; Guiter J; Navratil H
    Prog Urol; 1997 Sep; 7(4):622-7. PubMed ID: 9410322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
    Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
    J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience.
    Sturgeon JF; Moore MJ; Kakiashvili DM; Duran I; Anson-Cartwright LC; Berthold DR; Warde PR; Gospodarowicz MK; Alison RE; Liu J; Ma C; Pond GR; Jewett MA
    Eur Urol; 2011 Apr; 59(4):556-62. PubMed ID: 21190791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.